| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 First Department of Internal Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113
2 Daiichi Pharmaceutical, Tokyo 134
3 Department of Virology II, National Institute of Health, Tokyo 162
4 Laboratory of Molecular Genetics, Institute of Medical Science, University of Tokyo, Tokyo 108
and5 Institute of Medical Science, St Marianna University School of Medicine, Kawasaki 213, Japan
In an attempt to establish a model for hepatitis C virus (HCV) infection, we produced mice transgenic for the HCV envelope genes, E1 and E2, under the control of a regulatory element from hepatitis B virus. F1-generation mice from the established founders demonstrated expression of both E1 and E2 proteins as glycosylated forms in their organs including the liver. Immunostaining revealed the localization of envelope proteins principally in the cytoplasm of hepatocytes around the hepatic central veins. Furthermore, E1 and E2 proteins were shown by immunoprecipitation to be associated with each other in the mouse liver. There was no evidence of tissue pathology in the mouse liver up to 16 months of age, suggesting that E1 and E2 proteins per se may not have direct pathogenic effects. Our results demonstrate the first successful expression of HCV gene products in the mouse liver and the association of in vivo expressed HCV envelope proteins. This transgenic mouse would be a good model to study the virus-cell interactions of HCV such as intracellular transport and assembly of envelope proteins. Also it may be a good model system to determine the role of these proteins in the pathogenesis of hepatitis or extra-hepatic manifestations in HCV infection by the introduction of cytotoxic T lymphocytes specific for the envelope proteins.
* Author for correspondence. Fax +81 3 3812 5063. e-mail kkoike-tky@umin.u-tokyo.ac.jp
Received 11 May 1995;
accepted 18 August 1995.
This article has been cited by other articles:
|
|
 |
|
  T. Naas, M. Ghorbani, I. Alvarez-Maya, M. Lapner, R. Kothary, Y. De Repentigny, S. Gomes, L. Babiuk, A. Giulivi, C. Soare, et al. Characterization of liver histopathology in a transgenic mouse model expressing genotype 1a hepatitis C virus core and envelope proteins 1 and 2 J. Gen. Virol., August 1, 2005; 86(8): 2185 - 2196. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. F. Wieland and F. V. Chisari Stealth and Cunning: Hepatitis B and Hepatitis C Viruses J. Virol., August 1, 2005; 79(15): 9369 - 9380. [Full Text] [PDF]
|
|
|
|
|
|
S. U. Nielsen, M. F. Bassendine, A. D. Burt, D. J. Bevitt, and G. L. Toms Characterization of the genome and structural proteins of hepatitis C virus resolved from infected human liver J. Gen. Virol., June 1, 2004; 85(6): 1497 - 1507. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Moriya, K. Nakagawa, T. Santa, Y. Shintani, H. Fujie, H. Miyoshi, T. Tsutsumi, T. Miyazawa, K. Ishibashi, T. Horie, et al. Oxidative Stress in the Absence of Inflammation in a Mouse Model for Hepatitis C Virus-associated Hepatocarcinogenesis Cancer Res., June 1, 2001; 61(11): 4365 - 4370. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K Hiranuma, S Tamaki, Y Nishimura, S Kusuki, M Isogawa, G Kim, M Kaito, K Kuribayashi, Y Adachi, and Y Yasutomi Helper T cell determinant peptide contributes to induction of cellular immune responses by peptide vaccines against hepatitis C virus J. Gen. Virol., January 1, 1999; 80(1): 187 - 193. [Abstract]
|
|
|
|
 |
|
 K. Koike, K. Moriya, K. Ishibashi, H. Yotsuyanagi, Y. Shintani, H. Fujie, K. Kurokawa, Y. Matsuura, and T. Miyamura Sialadenitis histologically resembling Sjogren syndrome in mice transgenic for hepatitis C virus envelope genes PNAS, January 7, 1997; 94(1): 233 - 236. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| INT J SYST EVOL MICROBIOL | MICROBIOLOGY | J GEN VIROL |
| J MED MICROBIOL | ALL SGM JOURNALS | |
